PBE News and Press, Invesco Dynamic Biotech & Genome From 03/06/24

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...

2024-02-23 04:05:00 ET Summary Within healthcare, an area that has been negatively impacted the last couple of years is the pharmaceutical manufacturing value chain. Several capital goods and materials sectors experienced recessionary conditions last year, which caused weak fundam...

2024-02-07 01:53:00 ET Summary A sub-$3trn 2023 for M&A, but new year pipeline gives hope. Rising follow-on equity in 2023 signals latent appetite. Unstoppable debt capital markets hit $8.9trn for FY2023. By Lucille Jones, Senior Manager, Deals Intelligence and...

2024-01-31 04:36:00 ET Summary 2023 was characterized by narrow leadership and multiple expansions. While last year’s gains have led to headline valuations appearing stretched, there are many segments of the market that are not as aggressively priced. With the expectati...

2024-01-16 04:50:00 ET Summary Why US banks could be poised for a rebound? Sectors primed for a pivot if the Fed cuts. The outlook for healthcare and real estate. The potential for interest rate cuts this year by the U.S. Federal Reserve is raising the outlook for ...

2024-01-16 03:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-15 12:40:00 ET Summary All decisions around investing, everything we're seeing everyone doing is now colored by the rate situation. Artificial intelligence is a constantly growing and transforming phenomenon. Unlike artificial intelligence, a lot of the most exciting a...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...